Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 5Endocrine 5Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Lung Neoplasms 96Adenocarcinoma of Lung 39Colorectal Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 19Neoplasms 18Small Cell Lung Carcinoma 13Non-Squamous Non-Small Cell Lung Cancer 13Brain Neoplasms 13Neoplasm Metastasis 10Ovarian Neoplasms 9Pleural Effusion, Malignant 8Breast Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Meningeal Carcinomatosis 7Mesothelioma 6Melanoma 6Endometrial Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Rectal Neoplasms 4Non-squamous Non-small Cell Lung Cancer 4Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Non-small Cell Lung Cancer Metastatic 3Mesothelioma, Malignant 3Esophageal Neoplasms 3Colonic Neoplasms 3

Interventions

Nivolumab 3Cyclophosphamide 3pembrolizumab 2fludarabine phosphate 2fludarabine 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2Everolimus 2Carboplatin 2tislelizumab 1taxane 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1olaparib 1liposomal doxorubicin 1entrectinib 1cabozantinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1RRx-001 1Quality of Life 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Bevacizumab × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡